GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (NYSE:NVS) » Definitions » Piotroski F-Score
中文

Novartis AG (Novartis AG) Piotroski F-Score : 7 (As of Apr. 24, 2024)


View and export this data going back to 1996. Start your Free Trial

Novartis AG Definition

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis AG has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Novartis AG's Piotroski F-Score or its related term are showing as below:

NVS' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 7   Max: 7
Current: 7

During the past 13 years, the highest Piotroski F-Score of Novartis AG was 7. The lowest was 4. And the median was 7.


Novartis AG Piotroski F-Score Historical Data

The historical data trend for Novartis AG's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novartis AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 5.00 7.00 6.00 7.00

Novartis AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 6.00 6.00 6.00 7.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Novartis AG's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was 2293 + 2316 + 1761 + 8480 = $14,850 Mil.
Cash Flow from Operations was 2957 + 3576 + 5378 + 2547 = $14,458 Mil.
Revenue was 13208 + 13936 + 12092 + 11776 = $51,012 Mil.
Gross Profit was 9277 + 9595 + 8975 + 8754 = $36,601 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(117453 + 112241 + 110979 + 112697 + 99945) / 5 = $110663 Mil.
Total Assets at the begining of this year (Dec22) was $117,453 Mil.
Long-Term Debt & Capital Lease Obligation was $20,034 Mil.
Total Current Assets was $30,481 Mil.
Total Current Liabilities was $26,390 Mil.
Net Income was 2222 + 1694 + 1573 + 1466 = $6,955 Mil.

Revenue was 12814 + 13085 + 10783 + 10966 = $47,648 Mil.
Gross Profit was 8958 + 9334 + 7909 + 7925 = $34,126 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(131795 + 125218 + 122910 + 118464 + 117453) / 5 = $123168 Mil.
Total Assets at the begining of last year (Dec21) was $131,795 Mil.
Long-Term Debt & Capital Lease Obligation was $21,782 Mil.
Total Current Assets was $36,910 Mil.
Total Current Liabilities was $28,656 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis AG's current Net Income (TTM) was 14,850. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis AG's current Cash Flow from Operations (TTM) was 14,458. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=14850/117453
=0.12643355

ROA (Last Year)=Net Income/Total Assets (Dec21)
=6955/131795
=0.05277135

Novartis AG's return on assets of this year was 0.12643355. Novartis AG's return on assets of last year was 0.05277135. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Novartis AG's current Net Income (TTM) was 14,850. Novartis AG's current Cash Flow from Operations (TTM) was 14,458. ==> 14,458 <= 14,850 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=20034/110663
=0.18103612

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=21782/123168
=0.17684788

Novartis AG's gearing of this year was 0.18103612. Novartis AG's gearing of last year was 0.17684788. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=30481/26390
=1.15502084

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=36910/28656
=1.28803741

Novartis AG's current ratio of this year was 1.15502084. Novartis AG's current ratio of last year was 1.28803741. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Novartis AG's number of shares in issue this year was 2074. Novartis AG's number of shares in issue last year was 2158. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=36601/51012
=0.71749784

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=34126/47648
=0.71621054

Novartis AG's gross margin of this year was 0.71749784. Novartis AG's gross margin of last year was 0.71621054. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=51012/117453
=0.43431841

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=47648/131795
=0.36153117

Novartis AG's asset turnover of this year was 0.43431841. Novartis AG's asset turnover of last year was 0.36153117. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+0+1+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis AG has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Novartis AG  (NYSE:NVS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Novartis AG Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Novartis AG's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG (Novartis AG) Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Novartis AG (Novartis AG) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Moser Wealth Advisors, LLC

By GuruFocus Research GuruFocus Editor 08-03-2022